Literature DB >> 11328859

Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner.

A T Reutens1, M Fu, C Wang, C Albanese, M J McPhaul, Z Sun, S P Balk, O A Jänne, J J Palvimo, R G Pestell.   

Abstract

The androgen receptor (AR) is a ligand-regulated member of the nuclear receptor superfamily. The cyclin D1 gene product, which encodes the regulatory subunit of holoenzymes that phosphorylate the retinoblastoma protein (pRB), promotes cellular proliferation and inhibits cellular differentiation in several different cell types. Herein the cyclin D1 gene product inhibited ligand-induced AR- enhancer function through a pRB-independent mechanism requiring the cyclin D1 carboxyl terminus. The histone acetyltransferase activity of P/CAF (p300/CBP associated factor) rescued cyclin D1-mediated AR trans-repression. Cyclin D1 and the AR both bound to similar domains of P/CAF, and cyclin D1 displaced binding of the AR to P/CAF in vitro. These studies suggest cyclin D1 binding to the AR may repress ligand-dependent AR activity by directly competing for P/CAF binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328859     DOI: 10.1210/mend.15.5.0641

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  72 in total

1.  Lysine methylation and functional modulation of androgen receptor by Set9 methyltransferase.

Authors:  Soyoung Ko; Jungmi Ahn; Chung S Song; Soyoung Kim; Katarzyna Knapczyk-Stwora; Bandana Chatterjee
Journal:  Mol Endocrinol       Date:  2011-01-27

2.  ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice.

Authors:  Mathew C Casimiro; Marco Crosariol; Emanuele Loro; Adam Ertel; Zuoren Yu; William Dampier; Elizabeth A Saria; Alex Papanikolaou; Timothy J Stanek; Zhiping Li; Chenguang Wang; Paolo Fortina; Sankar Addya; Aydin Tozeren; Erik S Knudsen; Andrew Arnold; Richard G Pestell
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

3.  Transcriptional regulation by a DNA-associated form of cyclin D1.

Authors:  Frédéric Bienvenu; Benjamin Barré; Sandrine Giraud; Sylvie Avril; Olivier Coqueret
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

Review 4.  Cyclins, cyclin dependent kinases, and regulation of steroid receptor action.

Authors:  N L Weigel; N L Moore
Journal:  Mol Cell Endocrinol       Date:  2007-01-05       Impact factor: 4.102

Review 5.  New roles of cyclin D1.

Authors:  Richard G Pestell
Journal:  Am J Pathol       Date:  2013-07       Impact factor: 4.307

6.  A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels.

Authors:  Tamzin M Tanner; Sarah Denayer; Bart Geverts; Nora Van Tilborgh; Stefanie Kerkhofs; Christine Helsen; Lien Spans; Vanessa Dubois; Adriaan B Houtsmuller; Frank Claessens; Annemie Haelens
Journal:  Cell Mol Life Sci       Date:  2010-02-26       Impact factor: 9.261

Review 7.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

8.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

9.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

Review 10.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.